BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Ecosystem innovation at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
84 organizations at BIO-Europe 2026 present work in ecosystem innovation: 33 drug developers, 21 academic, government and non-profit bodies, 16 service providers and 14 investors. Between them they bring 131 presentations to the program. Most represented: Merck KGaA (11 on the program), Bayer (6 on the program), Boehringer Ingelheim (5 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–9 of 84 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Merck KGaA Darmstadt, Germany | ◆Platinum Sponsor |
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Panel Tue Nov 10 14:00–14:45 Immunology under the microscope: New frontiers What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering. Talk Tue Nov 10 09:15–09:30 Pharma Presentation: Merck Merck's three businesses: medicines for diseases such as multiple sclerosis and cancer, tools for scientists, and technology for electronics. Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Bayer Leverkusen, Germany | ◆Platinum Sponsor |
Life sciences company with pharmaceuticals, consumer health and crop science divisions. | Talk Tue Nov 10 09:00–09:30 An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. Panel Tue Nov 10 16:30–16:55 The Role of Innovation in Biopharma Growth How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. Panel Wed Nov 11 11:00–12:00 Collaborative Innovation in CDMO Partnerships How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle. |
Boehringer Ingelheim Ingelheim am Rhein, Germany | ◆Platinum Sponsor |
Family-owned pharmaceutical company developing human and animal health medicines. | Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Talk Tue Nov 10 09:30–09:45 Pharma Presentation: Boehringer Ingelheim Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Informa London, United Kingdom | |
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy. | Keynote Mon Nov 9 10:15–10:30 Talk Mon Nov 9 09:30–10:00 partneringONE essentials workshop Newcomers learn what to expect from partnering meetings, including timing and etiquette, and how to get the most from the partneringONE system. Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. Talk Tue Nov 10 11:30–12:00 partneringONE power up workshop Experienced delegates learn advanced partneringONE features and team habits that save time and raise how often their meeting requests are accepted. Panel Wed Nov 11 13:00–13:45 BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers. Panel Wed Nov 11 09:00–09:45 How is the APAC region reshaping global biopharma? How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner. |
Johnson & Johnson New Brunswick, NJ | ◆Platinum Sponsor · Johnson & Johnson Innovation |
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Tue Nov 10 10:00–10:25 Regulatory Updates for Orphan and Pediatric Medicines How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 12:00–12:45 What's Next for Biomanufacturing Strategies? Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up. |
European Commission Brussels, Belgium | |
Executive body of the European Union, proposing legislation and running EU programmes, including health, medicines and research policy. | Panel Tue Nov 10 09:00–09:45 Accelerating Innovation and Market Exclusivity Through Regulatory Incentives How updated EU drug laws and the Biotech Act change how long new medicines are shielded from competing copies, compared with rules elsewhere. Panel Tue Nov 10 14:30–14:55 Investing in Women’s Health: How Can Europe Scale Innovation? How Europe can grow investment in women's health, previewing a European Investment Bank study of the field's research, unmet needs and funding options. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
CSL Behring King of Prussia, PA | ◆Platinum Sponsor |
CSL's biotherapeutics business, making plasma-derived and recombinant therapies for rare and serious diseases. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Tue Nov 10 14:00–14:45 Harnessing Regulatory Sandboxes to Drive Innovation in Novel Therapeutics & Technologies How regulatory sandboxes, where regulators let new products be tested under adjusted rules, could support new therapies and health technologies in Europe. |
EUCOPE Brussels, Belgium | |
Trade association representing small and mid-sized innovative pharmaceutical and biotech companies in Europe. | Panel Tue Nov 10 10:30–10:55 Addressing Unmet Medical Needs in Europe’s Evolving Pharmaceutical Landscape How regulators judge which diseases lack good treatments, which faster approval routes apply, and whether recent EU drug law changes have helped. Panel Wed Nov 11 12:00–12:45 HTA Regulation: Early Insights and Reimbursement Implications Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Miltenyi Biomedicine Bergisch Gladbach, Germany | |
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change. |
Find buyers in ecosystem innovation
Tell us what you sell and we’ll find the people at organizations working on ecosystem innovation most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction